Gain Therapeutics, Inc. (GANX)

Over the past six months, Gain Therapeutics, Inc.'s stock experienced a 52-week low of $1.41 and a 52-week high of $4.34. Positive clinical study results from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease were announced. The company received reiterated "Buy" ratings and increased price targets from analysts. Gain Therapeutics announced its participation in significant industry events. The company filed a prospectus supplement for a $35.5 million stock offering and a $100 million mixed shelf filing. Short interest in Gain Therapeutics, Inc. reportedly rose by 28.6%.

Gain Therapeutics, Inc. does not currently have commercial products on the market, so traditional demand seasonality is not a relevant factor. Information regarding demand seasonality for its future products is not readily available.

Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel small molecule therapeutics, operating within the Healthcare sector. The company utilizes its Magellan platform to identify new allosteric binding sites on disease-implicated proteins, aiming to discover first-in-class small molecules. Its lead drug candidate, GT-02287, is in a Phase 1b clinical study for Parkinson's disease. The company has other drug candidates in discovery, research, and preclinical stages targeting various therapeutic areas.

Gain Therapeutics, Inc. has operations in Switzerland, Spain, the United States, and Australia. The company's corporate office is located in Bethesda, Maryland, United States.

Gain Therapeutics, Inc. has maintained a generally positive brand reputation over the past year, largely driven by encouraging clinical trial results and favorable analyst sentiment. The company has received a consensus rating of "Strong Buy" or "Moderate Buy" from analysts. Potential risks that could affect its reputation include possible delays in advancing preclinical candidates to clinical studies, unexpected safety issues during trials, and regulatory hurdles. The company faces market dynamics such as slower-than-expected uptake and partnership risks, along with potential near- to medium-term dilution risks.

The ownership structure of Gain Therapeutics (GANX) stock is a mix of institutional, retail, and individual investors. Approximately 2.95% of the company's stock is owned by Institutional Investors, 3.33% by Insiders, and 93.72% by Public Companies and Individual Investors. Major institutional owners and shareholders include Jones Financial Companies Lllp, Vanguard Group Inc, DME Capital Management, LP, Vanguard Extended Market Index Fund Investor Shares (VEXMX), Citadel Advisors Llc, Geode Capital Management, Llc, Cambridge Investment Research Advisors, Inc., Marshall Wace, Llp, Morgan Stanley, Renaissance Technologies Llc, Edward Jones Trust Company, Greenlight Capital, Inc., and BlackRock, Inc. Khalid Islam is noted as owning the most shares of Gain Therapeutics (GANX) among individual investors.